Gilead CFO sells $432,689 in stock as shares rally on drug and M&A headlines
Gilead Sciences Chief Financial Officer Andrew D. Dickinson sold 3,000 shares on March 16, 2026, at $144.23 per share, a transaction valued at $432,689. The sale occurred while the stock was trading near $144.40 and following notable clinical and corporate developments, including positive Phase 3 HIV data, a $7.8 billion acquisition, and favorable …